|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2008-2-4
|
|
pubmed:abstractText |
Cilostazol, a phosphodiesterase III inhibitor, is indicated to treat the symptoms of intermittent claudication and increase walking distance in patients with peripheral arterial disease (PAD). At the time of approval, the United States Food and Drug Administration required an additional long-term safety study to evaluate the effect cilostazol on mortality.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0741-5214
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
330-336
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18155871-Aged,
pubmed-meshheading:18155871-Cardiovascular Diseases,
pubmed-meshheading:18155871-Double-Blind Method,
pubmed-meshheading:18155871-Female,
pubmed-meshheading:18155871-Hemorrhage,
pubmed-meshheading:18155871-Humans,
pubmed-meshheading:18155871-Intermittent Claudication,
pubmed-meshheading:18155871-Kaplan-Meier Estimate,
pubmed-meshheading:18155871-Male,
pubmed-meshheading:18155871-Middle Aged,
pubmed-meshheading:18155871-Patient Compliance,
pubmed-meshheading:18155871-Peripheral Vascular Diseases,
pubmed-meshheading:18155871-Phosphodiesterase Inhibitors,
pubmed-meshheading:18155871-Proportional Hazards Models,
pubmed-meshheading:18155871-Risk Assessment,
pubmed-meshheading:18155871-Tetrazoles,
pubmed-meshheading:18155871-Time Factors,
pubmed-meshheading:18155871-Treatment Outcome,
pubmed-meshheading:18155871-United States
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
|
|
pubmed:affiliation |
Section of Vascular Medicine, Divisions of Geriatrics and Cardiology, University of Colorado School of Medicine C/O Colorado Prevention Center, Denver, CO 80203, USA. Will.Hiatt@UCHSC.edu <Will.Hiatt@UCHSC.edu>
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase IV
|
